Buddy Ratner is the Michael and Mryna Darland Chair in Technology Commercialization, Professor, Bioengineering and Chemical Engineering, University of Washington (UW) and Director-UWEB21. Received his Ph.D. 1972 from Polytechnic Institute Brooklyn. His specializations are biomaterials, biocompatibility, biomedical engineering, biosurface engineering. He is a fellow AIMBE, AVS, AAAS, ACS, and Society For Biomaterials (SFB). Elected to National Academy Engineering, USA (2002). Awards include AVS Welch (2002), SFB Founders (2004), the BMES Pritzker Lecturer (2008), the Acta Biomaterialia Gold Medal (2009), the Galletti Award (2011) the George Winter Award, European Society for Biomaterials (2012), UW Medicine Lifetime Innovator/Inventor Award (2014), ACS Bioelastomers Award (2021). He served as President of SFB (1998) and AIMBE (2002). He was lead editor, "Biomaterials Science: An Introduction to Materials in Medicine” (1st, 2nd and 3rd editions). Ratner has started 7 companies, most recently, Kuleana Technology, Inc.
Gaurav Sahay, Ph.D., is a Professor in the Department of Pharmaceutical Sciences and Director of the Center for Innovative Drug Delivery and Imaging (CIDDI) at Oregon State University. His research focuses on the development of lipid nanoparticle (LNP) technologies for the delivery of messenger RNA (mRNA), gene-editing systems, and other nucleic acid therapeutics to treat diseases including cystic fibrosis, retinal degeneration, and cancer. Dr. Sahay is internationally recognized for his pioneering contributions to understanding intracellular trafficking and endosomal escape, key biological barriers that limit the effectiveness of nucleic acid therapeutics. His work has advanced fundamental knowledge of how nanoparticles interact with cells and has led to the development of innovative delivery strategies that enhance cytosolic transport and therapeutic efficacy. He has authored more than 80 peer-reviewed publications in leading scientific journals, including Nature, Nature Biotechnology, Nature Nanotechnology, Nature Communications, and Science Advances. His research has been supported by major funding from the National Institutes of Health (NIH), the Defense Advanced Research Projects Agency (DARPA), the Cystic Fibrosis Foundation, and multiple industry partners. Dr. Sahay’s contributions have been recognized through numerous honors, including the AAPS Postdoctoral Fellow Award, the Controlled Release Society (CRS) T. Nagai Award, the AACP New Investigator Award, the OHSU Distinguished Faculty Senate Award, the PKP Emerging Scholar Award, and the CMBE Young Innovator Award. He was elected a Fellow of the Controlled Release Society (CRS) in 2024 and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) in 2026. In addition to his academic leadership, Dr. Sahay is actively engaged in translating scientific discoveries into clinical applications. He is a co-founder of EnterX Bio, RNAvax Bio and has played a significant role in advancing next-generation RNA medicines and nanoparticle-based therapeutics from the laboratory toward commercialization and patient care.
Dr. Teresa Rapp grew up in Oak View, CA, where she began her higher education at the local community college, earning an A.A. at Ventura College in 2009. She completed her B.S. in Chemistry at Cal Poly San Luis Obispo in 2012, where she performed chemical education research with Prof. Derek Gragson. Looking for a change, Dr. Rapp moved to Philadelphia, where she trained for her PhD at the University of Pennsylvania under Prof. Ivan Dmochowski. It was in the Dmochowski lab that she discovered the potential of ruthenium compounds applied to biological problems, especially hydrogel biomaterials after collaborating with the Burdick lab in Penn Bioengineering. To expand her skill set, Dr. Rapp pursued a postdoc with Prof. Cole DeForest at the University of Washington, where she published multiple reviews on visible light-sensitive biomaterials and two novel applications of ruthenium crosslinkers in biomaterials (Nat. Comm. and JACS). In 2023, she moved to Eugene, OR, to begin her independent career in the Department of Chemistry and Biochemistry at the University of Oregon, building a lab that leverages inorganic chemistry to direct biological events. When she's not in the lab, Dr. Rapp enjoys the beautiful Eugene summers exploring the local hiking and camping spots, and the rainy winters hosting get-togethers at home.
Dr. Cristiane Miranda Franca is a clinician-scientist and Assistant Professor at the Oregon Health & Science University School of Dentistry and a core member of the Knight Cancer Institute Precision Biofabrication Hub. Trained in pathology, tissue engineering, and microfluidics, she works at the interface of engineering and biology to develop human-relevant disease models. Her research focuses on engineering blood and lymphatic vascular systems to define how interactions among cancer cells, the extracellular matrix, and the vasculature regulate local immune responses and disease progression. Through engineered tissues and organ-on-a-chip technologies, she generates mechanistic insight into human disease and is advancing these platforms toward scalable, predictive systems for target discovery and therapeutic development.